SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 13.4% Stake in Nurix Therapeutics Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 13.4% of Nurix Therapeutics Inc.'s common stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively reported beneficial ownership of 10,246,211.12 shares of Nurix Therapeutics Inc. common stock.
• This ownership represents 13.4% of the total outstanding common stock of Nurix Therapeutics Inc.
• FMR LLC, a Delaware-based entity, holds sole voting power over 10,243,661.00 shares and sole dispositive power over 10,246,211.12 shares.
• Abigail P. Johnson, a U.S. citizen, holds sole dispositive power over 10,246,211.12 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported beneficial ownership.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Nurix Therapeutics Inc.
• FMR LLC's subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities that beneficially own shares, with Fidelity Management & Research Company LLC owning 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information regarding the operational or financial positives of Nurix Therapeutics Inc.

Negatives

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information regarding the operational or financial negatives of Nurix Therapeutics Inc.

Risks

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information regarding specific risks related to Nurix Therapeutics Inc.'s operations or financial condition.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Nurix Therapeutics Inc. management.

Industry Context

This Schedule 13G filing is a disclosure of beneficial ownership by a major institutional investor and does not provide specific analysis of broader industry trends or competitors for Nurix Therapeutics Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by FMR LLC and Abigail P. Johnson provides transparency regarding major ownership positions, which can influence investor perception and confidence.

Key Dates

Keywords

Nurix Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Disclosure